Home » BARR BOARD REAFFIRMS COMMITMENT TO HANFA TAKEOVER PROCESS

BARR BOARD REAFFIRMS COMMITMENT TO HANFA TAKEOVER PROCESS

July 6, 2006

Barr Pharmaceuticals, Inc. today announced that the Company's Board of Directors unanimously reaffirmed its commitment to the official Croatian Financial Services Supervisory Agency (HANFA) takeover process for Zagreb, Croatia-based PLIVA d.d.
Drug Newswire

KEYWORDS FDAnews Drug Daily Bulletin

05Dec
Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing
07Dec
Proactive Supplier Management Using Quality Agreements
13Dec
FDA Inspection Overhaul: How Things Have Changed in 2023
14Apr
MAGI 2024: The Clinical Research Conference

BARR BOARD REAFFIRMS COMMITMENT TO HANFA TAKEOVER PROCESS

Upcoming Events

Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

Proactive Supplier Management Using Quality Agreements

FDA Inspection Overhaul: How Things Have Changed in 2023

MAGI 2024: The Clinical Research Conference

Featured Products

FDA, FTC and DOJ Enforcement of Medical Device Regulations

Using Real-World Evidence in Drug and Device Submissions

Featured Stories

T-cell Malignancy From CAR-T Cell Immunotherapies Gets FDA Investigation

Vivos Sleep Apnea Oral Device Gets FDA Nod While Philips Wrestles With Yet Another CPAP Safety Issue

Novo Nordisk Battles Wegovy/Ozempic Pretenders and Faces Mounjaro’s Superior Study Results

Social, Emotional Risks Associated With Multi-Cancer Screening Discussed by Adcomm

The Revised ICH E8: A Guide to New Clinical Trial Requirements